Thermo Fisher Scientific (TMO) EBIT (2009 - 2026)

Thermo Fisher Scientific (TMO) has reported EBIT for 18 consecutive years, with $1.9 billion the latest figure, recorded in Q1 2026.

• EBIT for Q1 2026 came in at $1.9 billion, up 8.57% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.9 billion (up 6.81% YoY), and the FY2025 annual result was $7.7 billion, up 5.57% from the prior year.
• EBIT was $1.9 billion for Q1 2026 at Thermo Fisher Scientific, down from $2.3 billion in the prior quarter.
• Over five years, EBIT peaked at $2.8 billion in Q2 2022 and troughed at $1.6 billion in Q2 2023.
• Average EBIT over 5 years is $1.9 billion, with a median of $1.9 billion recorded in 2023.
• Year-over-year, EBIT tumbled 44.59% in 2023 and increased 15.34% in 2024.
• Over 5 years, EBIT stood at $1.9 billion in 2022, then slipped by 0.38% to $1.9 billion in 2023, then gained by 8.74% to $2.0 billion in 2024, then gained by 11.86% to $2.3 billion in 2025, then slipped by 17.38% to $1.9 billion in 2026.
• Per Business Quant data, the three most recent EBIT figures were $1.9 billion in Q1 2026, $2.3 billion in Q4 2025, and $1.9 billion in Q3 2025.